These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9091474)

  • 21. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
    Meffert H; Bräutigam M; Färber L; Weidinger G
    Acta Derm Venereol; 1997 Mar; 77(2):137-41. PubMed ID: 9111826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study.
    Reitamo S; Erkko P; Remitz A; Lauerma AI; Montonen O; Harjula K
    Arch Dermatol; 1993 Oct; 129(10):1273-9. PubMed ID: 8215491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine therapy for psoriasis: a cell cycle-derived dosing schedule.
    Goodman MM; White GM; McCormick A; McCullough J; Weinstein G
    J Am Acad Dermatol; 1992 Oct; 27(4):594-8. PubMed ID: 1401311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T; Furukawa F; Iwatsuki K; Matsue H; Shimada S; Takigawa M; Tokura Y
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study.
    Honeyman JF; Sánchez L; Valdés P
    Int J Dermatol; 1995 Aug; 34(8):583-8. PubMed ID: 7591445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.
    Borghi A; Corazza M; Mantovani L; Bertoldi AM; Giari S; Virgili A
    Int J Dermatol; 2012 Dec; 51(12):1512-6. PubMed ID: 23171021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
    Dermatology; 1993; 187 Suppl 1():8-18. PubMed ID: 8369579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study.
    Christophers E; Mrowietz U; Henneicke HH; Färber L; Welzel D
    J Am Acad Dermatol; 1992 Jan; 26(1):86-90. PubMed ID: 1732342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
    Ohtsuki M; Nakagawa H; Sugai J; Ozawa A; Ohkido M; Nakayama J; Hanada J; Morimoto Y; Jimbow K; Horikoshi T; Kitahara H; Tamaki K; Urabe K; Hori Y
    J Dermatol; 2003 Apr; 30(4):290-8. PubMed ID: 12707465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
    Gottlieb AB; Griffiths CE; Ho VC; Lahfa M; Mrowietz U; Murrell DF; Ortonne JP; Todd G; Cherill R; Marks I; Emady-Azar S; Paul CF;
    Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
    Atakan N; Erdem C
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):240-6. PubMed ID: 9883436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
    Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
    J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.